We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BGB-3245
Previous Study | Return to List | Next Study

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04249843
Recruitment Status : Recruiting
First Posted : January 31, 2020
Last Update Posted : January 3, 2022
Sponsor:
Information provided by (Responsible Party):
MapKure, LLC

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and antitumor activity of BGB-3245 in participants with advanced or refractory solid tumors

Condition or disease Intervention/treatment Phase
Solid Tumor B-Raf Mutation-Related Tumors Drug: BGB-3245 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 168 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human, Phase 1a/1b, Open Label, Dose-Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of the RAF Dimer Inhibitor BGB-3245 in Patients With Advanced or Refractory Tumors
Actual Study Start Date : February 17, 2020
Estimated Primary Completion Date : May 1, 2023
Estimated Study Completion Date : June 1, 2023

Arm Intervention/treatment
Experimental: Phase 1a: Dose Escalation
BGB-3245 administered orally (PO)
Drug: BGB-3245
administered orally (PO)

Experimental: Phase 1b, Group 1: Dose Expansion
BGB-3245 administered orally (PO)
Drug: BGB-3245
administered orally (PO)




Primary Outcome Measures :
  1. Phase 1a: Number of Participants and Severity Experiencing Adverse Events (AEs) [ Time Frame: Up to 30 days after the last dose of study drug ]
  2. Phase 1a: Number of Participants and Severity Experiencing Serious Adverse Events (SAEs) [ Time Frame: Up to 30 days after the last dose of study drug ]
  3. Phase 1a: number of Participants Experiencing AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria [ Time Frame: From Cycle 1 Day to the end of Cycle 1 (Cycle 1 is 30 days) ]
  4. Phase 1a: Maximum Tolerated Dose (MTD) of BGB-3245, and the recommended Phase 2 Dose (RP2D) for BGB-3245 [ Time Frame: From Cycle 1 Day to the end of Cycle 1 (Cycle 1 is 30 days) ]
    The MTD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 33%.

  5. Phase 1b: Objective Response Rate (ORR) confirmed Complete Response and Partial Response [ Time Frame: Up to 24 months ]

Secondary Outcome Measures :
  1. Phase 1a: Overall Response Rate (ORR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  2. Phase 1a: Duration of Response (DOR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  3. Phase 1a: Clinical Benefit Rate (CBR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  4. Phase 1a: Best Overall Response (BOR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  5. Phase 1a: Duration of Stable Disease (DSD) [ Time Frame: Up to 24 months ]
  6. Phase 1a: Progression Free Survival (PFS) [ Time Frame: Up to 24 months ]
  7. Phase 1a: Plasma Concentration of BGB-3245 [ Time Frame: Within 60 minutes predose up to 72 hours postdose ]
  8. Phase 1a: Maximum Observed Plasma Concentration (Cmax) of BGB-3245 [ Time Frame: Within 60 minutes predose up to 72 hours postdose ]
  9. Phase 1a: Time to Maximum Plasma Concentration (Tmax) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  10. Phase 1a: Time Taken for Half the Initial Dose Administered To Be Eliminated From The Body (T1/2) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  11. Phase 1a: Area Under the Concentration-Time Curve of 0-infinity Days (AUC0-inf) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  12. Phase 1a:Area Under the Concentration-Time Curve of 0-Last hour (AUC0-last) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  13. Phase 1a: Drug Clearance (CL/F) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  14. Phase 1a: Apparent Volume of Distribution (Vz/F) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  15. Phase 1a: Steady State Area Under the Concentration-Time Curve of 0- Last hour (AUCLast, ss) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  16. Phase 1a: Steady State Maximum Observed Plasma Concentration (Cmax, ss) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  17. Phase 1a: Steady State Time to Maximum Plasma Concentration (Tmax, ss) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]
  18. Phase 1b: Progression-free survival (PFS) as Assessed by the Investigator [ Time Frame: Up to 36 months ]
  19. Phase 1b: Duration of Response (DOR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  20. Phase 1b: Disease-Control Rate (DCR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  21. Phase 1b: Duration of Stable Disease (DSD) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  22. Phase 1b: Clinical Benefit Rate (CBR) as Assessed by the Investigator [ Time Frame: Up to 24 months ]
  23. Phase 1b: Overall Survival [ Time Frame: Up to 36 months ]
  24. Phase 1b: Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: Up to 30 days after the last dose of study drug ]
  25. Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs) [ Time Frame: Up to 30 days after the last dose of study drug ]
  26. Phase 1b: Plasma Concentration of BGB-3245 [ Time Frame: 60 minutes predose up to 3 hours postdose ]
  27. Phase 1b: Steady State Trough Observed Plasma Concentration (Ctrough, SS) of BGB-3245 [ Time Frame: 60 minutes predose up to 72 hours postdose ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  1. Participants with histologically confirmed advanced or metastatic solid tumor who have experienced disease progression during or after at least 1 line of prior systemic anticancer therapy, or for whom treatment is not available or not tolerated/acceptable to the participants. In addition, participants must meet the following eligibility criteria for the corresponding phase of the study:

    1. Phase 1a: participants with a known mutation status and tumor harboring an oncogenic mutation of the v-RAF murine sarcoma viral oncogene homolog B (BRAF) gene (the mutations of primary interest are the BRAF Class II mutation, Class III mutation or BRAF fusion). In addition, participants with melanoma harboring the mutation of the neuroblastoma RAS viral oncogene homolog (NRAS) gene are eligible for Part 1a.
    2. Phase 1b: participants must have a known mutation status and meet one of the following criteria according to the group they are enrolled into:

    i. Group 1: participants with solid tumors harboring a BRAF Class II mutation

    ii. Group 2: participants with solid tumors harboring a BRAF Class III mutation

    iii. Group 3: participants with solid tumors harboring a BRAF fusion mutation

    iv. Group 4: participants with cutaneous melanoma harboring a NRAS mutation

    v. Group 5: participants with cutaneous melanoma harboring a NRAS mutation that consent to paired fresh biopsies inhibitor resistant tumors.

  2. Participants must provide archival tumor tissue or agree to a fresh tumor biopsy for mutation and biomarkers analysis (fresh tumor biopsies are strongly recommended at Screening in participants with readily accessible tumor lesions who are not receiving anticoagulants).3. Patients must have radiologically measurable disease as defined per RECIST v1.1.

Key Exclusion Criteria:

  1. Participants receiving cancer therapy (chemotherapy or other systemic anticancer therapies, immunotherapy, radiation therapy, or surgery) at the time of Cycle 1 Day 1.
  2. All participants who have received prior systemic anticancer treatment within the following time frames will be excluded:

    1. Cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment (i.e., 6 weeks for nitrosourea, mitomycin C) prior to Cycle 1 Day 1; and
    2. Biologic therapy (i.e., antibodies), continuous or intermittent small-molecule therapies, or any other investigational agents within a period of 5 times the half-life of the agent or ≤4 weeks (whichever is shorter) prior to Cycle 1 Day 1.
  3. History or presence of gastrointestinal disease or other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
  4. Current evidence of symptomatic CNS metastases, leptomeningeal carcinomatosis or untreated spinal cord compression. Asymptomatic treated or asymptomatic untreated brain metastases are allowed as long as patients are clinically stable.
  5. Any unstable, preexisting major medical condition that in the opinion of the investigator contraindicates the use of a study drug, including known human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04249843


Contacts
Layout table for location contacts
Contact: MapKure 1-877-828-5568 clinicaltrials@mapkure.com

Locations
Layout table for location information
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
United States, New York
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
United States, Texas
MD Anderson Recruiting
Houston, Texas, United States, 77030
Australia
Peter MacCallum Cancer Centre Recruiting
Melbourne, Australia, 2010
The Kinghorn Cancer Centre, St Vincent Hospital Sydney Recruiting
Sydney, Australia, 2010
Sponsors and Collaborators
MapKure, LLC
Layout table for additonal information
Responsible Party: MapKure, LLC
ClinicalTrials.gov Identifier: NCT04249843    
Other Study ID Numbers: BGB-3245-AU-001
First Posted: January 31, 2020    Key Record Dates
Last Update Posted: January 3, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by MapKure, LLC:
BGB3245
B-RAF inhibitor
B-RAF
K-RAS
N-RAS
Mitogen Activated Protein Kinase (MAPK) Pathway
BRAF fusion
BRAF Class II
BRAF Class III
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms